Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bullboard - Stock Discussion Forum Omeros Corp OMER

Omeros Corporation is a biopharmaceutical company. The Company is focused on discovering, developing and commercializing small-molecule and protein therapeutics for large-market and orphan indications targeting immunologic disorders, including complement-mediated diseases, cancers, and addictive and compulsive disorders. Its lead MASP-2 inhibitor, narsoplimab, targets the lectin pathway of... see more

Bullboard (NDAQ:OMER)

View:
User Avatar Image
(110)
•••
  • StockHorizX
Post by StockHorizon Nov 25, 2024 10:12am

Biotech Bulls: $MYNZ and $OMER Riding FDA Wave

$OMER is rallying on FDA-related optimism, driven by advancements in treatment devices. $MYNZ, with its cutting-edge cancer diagnostic capabilities, is positioned to benefit from the same sector buzz. ...more  
User Avatar Image
(9)
•••
  • MikeTesterX
Post by MikeTesteron Aug 02, 2024 6:10am

Omeros Corporation (NASDAQ:OMER): A Promising Biotech Poised

https://beyondspx.com/2024/08/01/omeros-corporation-nasdaqomer-a-promising-biotech-poised-for-significant-growth/
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities